XOMA to Present at the Cantor Fitzgerald Healthcare Conference
July 05 2016 - 2:06PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today that Dr.
Paul Rubin, the Company’s Senior Vice President, Research and
Development & Chief Medical Officer, is scheduled to present at
the Cantor Fitzgerald Healthcare Conference on Tuesday, July 12,
2016, at 9:30 a.m. ET.
A live audio webcast of the presentation can be
accessed in the Investors and Media section of XOMA's website at
http://investors.xoma.com/events.cfm. An archived version of the
webcast will be available via replay for 60 days following the
presentation.
About XOMA CorporationXOMA
Corporation is a leader in the discovery and development of
therapeutic antibodies. The Company's innovative product candidates
result from its expertise in developing ground-breaking monoclonal
antibodies, including allosteric antibodies, which have created new
opportunities to potentially treat a wide range of human diseases.
XOMA's scientific research has produced a portfolio of five
endocrine assets, each of which has the opportunity to address
multiple indications. The Company's lead product candidate, XOMA
358, is an allosteric monoclonal antibody that reduces insulin
receptor activity, which could have a major impact on the treatment
of hyperinsulinism. The Company recently initiated Phase 2
development activities for XOMA 358 in patients with congenital
hyperinsulinism and in patients who experience hypoglycemia
following gastric bypass surgery. For more information, visit
www.xoma.com.
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Taryn Ibach
W2O Group
415-658-9748
tibach@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024